PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
PTC Therapeutics (NASDAQ: PTCT) will host a webcast conference call to report its second quarter 2026 financial results and provide a business and outlook update on Thursday, July 30, 2026, at 4:30 p.m. ET.
Rhea-AI Summary
PTC Therapeutics (NASDAQ: PTCT) will host a webcast conference call to report its second quarter 2026 financial results and provide a business and outlook update on Thursday, July 30, 2026, at 4:30 p.m. ET. Investors can access the live webcast and a 30-day replay via the Investors "Events & Presentations" page on the PTC website. Phone participants are required to register in advance to receive dial-in details.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PTCT
In the Jul 16 session, PTCT declined 0.41%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings call time
- 4:30 p.m. ET
- Scheduled time for 2Q26 financial results webcast on July 30, 2026
- Webcast replay period
- 30 days
- Replay availability on company website following the 2Q26 results event
Previous Earnings date Reports
-
Scheduled webcast to report 24‑month PIVOT‑HD long‑term extension study results.
-
Announced timing and format for first quarter 2026 earnings release.
-
Set date and webcast details for Q4 and full‑year 2025 results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to receive dial-in details.
About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Facebook and Instagram.
For more information, please contact:
Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com
Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-to-report-second-quarter-2026-financial-results-on-thursday-july-30-2026-302826736.html
SOURCE PTC Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.